login english language greek language

 

Lipomed

 

  
 

 The Company

LIPOMED is a private Swiss Health Care Company. We are one of the leading companies for Reference Standards worldwide and specialized in the research, development and manufacturing of ethical pharmaceuticals and products for the treatment of rare diseases.

Since 1993 Lipomed is dedicated to providing products and services of outstanding quality and expertise.

We have our own GMP/GDP and ISO 9001 certified pharmaceutical production facilities in Arlesheim near Basel. We are also ISO/IEC 17025 accredited for testing of analytical reference standards and ISO Guide 34 accredited for the production of reference material.

Our innovative products are marketed and distributed with offices and partners in more than 50 countries around the world. 
 

Quality / ISO

LIPOMED AG, Switzerland is GMP/GDP and ISO 9001 certified for production and distribution of Pharmaceuticals and ISO/IEC 17025 (ANAB Certificate No. AT-1760) accredited for testing of Analytical Reference Standards and ISO Guide 34 (ANAB Certificate No. AR-1761) accredited for Reference Material production. All products distributed by LIPOMED affiliates are manufactured by LIPOMED AG and distributed under protocols of LIPOMED AG.
Additionally, the Pharma Marketing of LIPOMED is certified according to the "Référentiel de certification de la visite médicale" by the French Authorities. 

 

 Products

 

Analytical Reference Standards

Lipomed AG’s Reference Standards include the following classes of substances, their deuterated analogues and metabolites, such as Glucuronides and Sulfates, which are available as calibrated ready to use (RTU) solutions, ready to use calibrated (RTU) powders and bulk powders in standard size packaging.

 

Lipomed Reference Standards are available as calibrated ready to use (RTU) solutions and as calibrated ready to use (RTU) powders filled in ampules or in 20 ml vials respectively. 
  

Lipomed Reference Standards are also available as powders in standard pack sizes of 10 mg, 50 mg and 100 mg.

Lipomed Reference Standards are not to be used for any controlled preclinical or clinical studies. 

 

 

New Products

#ProductCAS
MAR-1699-FB4-Methylaminorex3568-94-3
DMR-1792-FBcis-(±)-4,4’-Dimethylaminorex1632031-39-0
FLV-1796-MAFluvoxamine.maleate61718-82-9
TAP-1809-HCTapentadol-D3.HCl1435782-38-9
VRP-1790-HCVerapamil.HCl152-11-4
LPR-1789-HCLoperamide.HCl34552-83-5
OXC-1751Oxcarbazepine28721-07-5
AMI-1788-HCAmitriptyline-D3.HCl342611-00-1
CPZ-1752-HCChlorpromazine.HCl69-09-0
COC-207-HCCocaethylene.HCl529-38-4

 

 

Pharmaceuticals
 

Lipomed AG’s focus is on research, manufacturing and distribution of niche pharmaceuticals for the treatment of rare diseases.

 

Litak®

(2 mg/ml, Cladribine, 2-chloro-2''''-deoxyadenosine, 2-CdA)

Cladribine is an antineoplastic agent of the following pharmacotherapeutic group: antineoplastic agents, antimetabolites, purine analogues (ATC-Code: L01BB04).

Litak® is a solution for injection that contains the active substance cladribine to treat rare forms of leukemia or lymphoma.

 

Dacin® / Dacarbazine Lipomed®

(100 mg, 200 mg freeze dried dacarbazine)

Dacarbazine, 5-(3, 3-Dimethyl-1-triazenyl) imidazole-4-carboxamide inhibits cancer cell proliferation by alkylation of DNA (ATC-Code: L01AX04).

Dacin® / Dacarbazine Lipomed® is a chemotherapeutic drug currently used to treat different forms of cancer.
 

Santuril®

(500 mg probenecid containing tablets)

Probenecid, (4-(dipropylsulfamoyl) benzoic acid inhibits the organic anion-transport across cell membranes by binding to to the relevant membrane transporter polypeptides thereby increasing urinary uric acid excretion while decreasing renal excretion and increasing plasma levels of drugs (ATC-Code: M04AB01).

Santuril® (500 mg Probenecid containing tablets) is an uricosuric agent.
 

Myrin®

(50, 100 mg thalidomide containing sugar coated tablets)

Thalidomide, (RS)-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione shows, both in vitro and in vivo, a multitude of biological responses, the most prominent of which are inhibition of angiogenesis and of TNF-α (ATC-Code: L04AX02). The anti angiogenic properties are clearly linked to thalidomide’s teratogenicity.

Myrin® is currently used in the treatment of cancer.

 

WARNING

If not prescribed and administered under strict control of a physician Myrin® can cause severe damage to newborns. Pregnant woman and woman capable of bearing children as well as procreative men are therefore not allowed to take Myrin® for any condition without a prescription from a physician.

 

Xaluprine®

(Mercaptopurine 20 mg/ml oral suspension)

6-mercaptopurine is an antineoplastic agent of the following pharmacotherapeutic group: antineoplastic agents, antimetabolites, purine analogues (ATC-Code: L01BB02).

Xaluprine® contains the active substance 6-mercaptopurine. It interferes with the metabolism of tumor cells, inhibiting their growth. It is used to treat a form of hematologic cancer in adults, adolescents and children.

 Please Contact us for more info

 Επιστροφή
Κεντρικά: Σταματίου Ψάλτου 30, 54644 Θεσσαλονίκη, Τηλ.: (+30) 2310-855844, Φαξ: (+30) 2310-886206
Υποκατάστημα: Μομφεράτου 131, 11475 Αθήνα, Τηλ.: (+30) 210-6452848, Φαξ: (+30) 210-6452413, www.megalab.gr, contact@megalab.gr

Created Alpha